Ingle L, Wilkinson M, Carroll S, Boyes C, Butterly R, King R, Cooke C, Cleland J, Clark A
Carnegie Research Institute, Leeds Metropolitan University, Beckett's Park Campus, Leeds, United Kingdom.
Int J Sports Med. 2007 Aug;28(8):678-84. doi: 10.1055/s-2007-964886. Epub 2007 Apr 13.
The six-minute walk test (6-MWT) is widely used to assess functional status in patients with chronic heart failure (CHF). The aims of the present study were: (1) to compare metabolic gas exchange during the 6-MWT in older patients with left ventricular systolic dysfunction (LVSD) and in breathless patients with no major structural heart disease (MSHD); (2) to determine the exercise intensity of the 6-MWT relative to peak oxygen uptake; (3) to establish the accuracy and reproducibility of the Metamax 3B ergospirometer during an incremental workload. Twenty four older patients with LVSD (19 male; age 76 +/- 5 years; BMI 27 +/- 4), and 18 patients with no MSHD (12 male; age 75 +/- 8 years; BMI 27 +/- 4) attended on consecutive days at the same time. Patients completed a 6-MWT with metabolic gas exchange measurements using the Metamax 3B portable ergospirometer, and an incremental cycle ergometry test using both the Metamax 3B and Oxycon Pro metabolic cart. Patients returned and performed a second 6-MWT and an incremental treadmill test, metabolic gas exchange was measured with the Metamax 3B. In patients with LVSD, the 6-MWT was performed at a higher fraction of maximal exercise capacity (p = 0.02). The 6-MWT was performed below the anaerobic threshold in patients with LVSD (83 %) and in patients with no MSHD (61 %). The Metamax 3B showed satisfactory to high accuracy at 10 W and 20 W in patients with LVSD (r = 0.77 - 0.97, p < 0.05), and no MSHD (r = 0.76 - 0.94, p < 0.05). Metabolic gas exchange variables measured during the 6-MWT showed satisfactory to high day-to-day reproducibility in patients with LVSD (ICC = 0.75 - 0.98), but a higher variability was evident in participants with no MSHD (ICC = 0.62 - 0.97). The Metamax 3B portable ergospirometer is an accurate and reproducible device during submaximal, fixed rate exercise in older patients with LVSD and no MSHD. In elderly patients with LVSD and no MSHD, the 6-MWT should not be considered a maximal test of exercise capacity but rather a test of submaximal exercise performance. Our study demonstrates that the 6-MWT takes place at a higher proportion of peak oxygen uptake in patients with LVSD compared to those with no MSHD, and may be one reason why fatigue is a more prominent symptom in these patients.
六分钟步行试验(6-MWT)被广泛用于评估慢性心力衰竭(CHF)患者的功能状态。本研究的目的是:(1)比较老年左心室收缩功能障碍(LVSD)患者和无重大结构性心脏病(MSHD)的气喘患者在6-MWT期间的代谢气体交换情况;(2)确定6-MWT相对于峰值摄氧量的运动强度;(3)确定Metamax 3B型呼吸代谢仪在递增负荷运动期间的准确性和可重复性。24例老年LVSD患者(19例男性;年龄76±5岁;体重指数27±4)和18例无MSHD患者(12例男性;年龄75±8岁;体重指数27±4)在连续的日子里于同一时间就诊。患者使用Metamax 3B便携式呼吸代谢仪完成6-MWT并测量代谢气体交换,同时使用Metamax 3B和Oxycon Pro代谢监测仪进行递增式自行车测力计测试。患者复诊并进行第二次6-MWT和递增式跑步机测试,使用Metamax 3B测量代谢气体交换。在LVSD患者中,6-MWT是在更高比例的最大运动能力下进行的(p = 0.02)。LVSD患者(83%)和无MSHD患者(61%)进行6-MWT时均低于无氧阈。Metamax 3B型呼吸代谢仪在LVSD患者(r = 0.77 - 0.97,p < 0.05)和无MSHD患者(r = 0.76 - 0.94,p < 0.05)中,在10 W和20 W时显示出令人满意至高度的准确性。在LVSD患者中,6-MWT期间测量的代谢气体交换变量显示出令人满意至高度的每日可重复性(组内相关系数ICC = 0.75 - 0.98),但在无MSHD的参与者中变异性更高(ICC = 0.62 - 0.97)。Metamax 3B便携式呼吸代谢仪在LVSD和无MSHD的老年患者进行次最大、固定速率运动期间是一种准确且可重复的设备。在老年LVSD和无MSHD患者中,6-MWT不应被视为运动能力的最大测试,而应被视为次最大运动表现的测试。我们的研究表明,与无MSHD的患者相比,LVSD患者进行6-MWT时达到峰值摄氧量的比例更高,这可能是这些患者疲劳症状更突出的原因之一。